Related Experiment Video

Updated: Jul 14, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4

Zhimin Xiang1, Irina D Pogozheva, Nicholas B Sorenson

  • 1Department of Medicinal Chemistry, University of Florida, Gainesville, Florida 32610, USA.

Biochemistry
|June 26, 2007
PubMed

Insights

Researchers identified specific ligands that can rescue the function of mutated human melanocortin-4 receptors (MC4R), which are linked to obesity. These findings offer potential therapeutic tools for understanding and treating obesity-related disorders.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Genetics

Background:

  • The melanocortin pathway, particularly the melanocortin-4 receptor (MC4R), is crucial for regulating energy balance and satiety.
  • Over 70 human MC4R gene variations (polymorphisms) have been identified in individuals with obesity, suggesting a role in the disease.
  • Understanding how these MC4R variations affect receptor function is key to developing targeted obesity treatments.

Purpose of the Study:

  • To investigate 13 specific MC4R gene variations associated with decreased function.
  • To identify synthetic peptides and small molecules that can restore the normal function of these mutated MC4R variants.
  • To explore potential pharmacological rescue strategies for MC4R-related obesity.

Main Methods:

  • Studied 13 distinct human MC4R (hMC4R) polymorphisms.
  • Tested the agonist potency of various synthetic ligands, including peptides (NDP-MSH, MTII, JRH887-9, Anc, JRH322-18, AMW3-130, AMW3-106) and small molecules (JB25, THIQ).
  • Assessed the ability of these ligands to rescue the reduced agonist response of the polymorphic hMC4Rs.

Main Results:

  • NDP-MSH, MTII, AMW3-130, THIQ, and AMW3-106 demonstrated nanomolar to subnanomolar agonist potency at the studied hMC4R polymorphisms.
  • These identified ligands effectively rescued the reduced potency and stimulatory response of the abnormally functioning hMC4Rs.
  • The study successfully identified ligands capable of pharmacologically rescuing the function of specific MC4R variants.

Conclusions:

  • Specific synthetic ligands, including NDP-MSH, MTII, AMW3-130, THIQ, and AMW3-106, can effectively restore the function of mutated MC4R.
  • These ligands may serve as valuable tools for further research into the molecular mechanisms underlying MC4R dysfunction in obesity.
  • The findings offer a promising avenue for developing novel therapeutic strategies targeting MC4R for obesity treatment.

More Related Videos

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Peptide-based Identification of Functional Motifs and their Binding Partners14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

Related Concept Videos

Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...